Document:

Document

Exhibit 10.3

THIRD OMNIBUS AMENDMENT TO SECURED NOTES 
AND SECOND AMENDMENT TO INTERCREDITOR AGREEMENT
This THIRD OMNIBUS AMENDMENT TO SECURED NOTES AND SECOND AMENDMENT TO INTERCREDITOR AGREEMENT (this “Amendment”), is entered into as of September 25, 2020, by and among HC2 STATION GROUP, INC., HC2 LPTV HOLDINGS, INC., HC2 BROADCASTING INC., HC2 NETWORK INC. (collectively, the “Subsidiary Borrowers”), HC2 BROADCASTING INTERMEDIATE HOLDINGS INC. (the “Intermediate Parent”), HC2 BROADCASTING HOLDINGS INC. (the “Parent Borrower” and, together with the Intermediate Parent and the Subsidiary Borrowers, the “Borrowers” and each, a “Borrower”), MSD PCOF PARTNERS XVIII, LLC (“MSD”), GREAT AMERICAN LIFE INSURANCE COMPANY (“GALIC”), and GREAT AMERICAN INSURANCE COMPANY (“GAIC”, and together with GALIC, “Great American”, and Great American together with MSD, the “Lenders”).
W I T N E S S E T H:
WHEREAS, pursuant to that certain Secured Note dated as of October 24, 2019 (the “MSD Secured Note”; the MSD Secured Note as amended by the Consent and First Amendment to Secured Note dated December 19, 2019, the First Omnibus Amendment to Secured Notes and Intercreditor Agreement dated February 21, 2020, the Consent dated August 17, 2020, the Consent dated August 31, 2020, the Consent to Asset Sale dated August 31, 2020, the Second Omnibus Amendment to Secured Notes dated August 31, 2020, and by this Amendment, the “Amended MSD Secured Note”), by and among the Borrowers and MSD, MSD made a Loan to the Borrowers pursuant to the terms and conditions thereof;
WHEREAS, pursuant to that certain Amended and Restated Secured Note dated as of October 24, 2019 (the “GA Secured Note”; the GA Secured Note as amended by the First Omnibus Amendment to Secured Notes and Intercreditor Agreement dated February 21, 2020, the Consent to Asset Sale dated August 31, 2020, the Second Omnibus Amendment to Secured Notes dated August 31, 2020, and this Amendment, the “Amended GA Secured Note”), by and among the Borrowers and Great American, Great American made a Loan to the Borrowers pursuant to the terms and conditions thereof;
WHEREAS, the relative rights and priorities of the security interests granted to the Lenders under the MSD Secured Note and the GA Secured Note are governed by the terms of that certain Intercreditor Agreement dated as of October 24, 2019 (the “Intercreditor Agreement”; the Intercreditor Agreement as amended by the First Omnibus Amendment to Secured Notes and Intercreditor Agreement dated February 21, 2020 and this Amendment, the “Amended Intercreditor Agreement”), by and among the Borrowers, MSD, and Great American;
WHEREAS, initially capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the MSD Secured Note; 
WHEREAS, the Borrowers have requested and MSD has agreed that the principal amount under the MSD Secured Note be increased by an additional $4,000,000; and

WHEREAS, the Borrowers have requested that the Lenders amend each of the MSD Secured Note, the GA Secured Note, and the Intercreditor Agreement that such Person is a party to in certain respects, and the Lenders are willing to do so, on the terms and subject to the conditions specified herein.
NOW, THEREFORE, in consideration of the foregoing and the mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each of the parties hereto hereby agrees as follows.
1.Amendments to MSD Secured Note.  Subject to the satisfaction of the conditions precedent to the Amendment Effective Date set forth in Section 4 below, the MSD Secured Note is amended as follows:
(a)The header on the first page of the MSD Secured Note is hereby amended by replacing the reference to “$39,296,568” appearing therein with “$43,296,568”.
(b)The preamble to the MSD Secured Note is hereby amended by replacing the reference to “Thirty Nine Million Two Hundred and Ninety Six Thousand Five Hundred and Sixty Eight Dollars ($39,296,568)” appearing therein with “Forty Three Million Two Hundred and Ninety Six Thousand Five Hundred and Sixty Eight Dollars ($43,296,568)”.
(c)Section 1 of the MSD Secured Note is hereby amended by adding the following new defined terms in the proper alphabetical order:
 “Second Additional Principal Amount” means $4,000,000.
“Third Omnibus Amendment” means that certain Third Omnibus Amendment to Secured Notes and Second Amendment to Intercreditor Agreement dated September 25, 2020 among the Borrowers, the Lender, and the Initial Lenders.
“Third Omnibus Amendment Effective Date” means the Amendment Effective Date, as defined in the Third Omnibus Amendment.
(d)Section 2.1 of the MSD Secured Note is hereby amended in its entirety as follows:
2.1    Disbursement. The Initial Principal Amount of this Note will be disbursed on the Closing Date to be used in accordance with Section 7.1(l). The Additional Principal Amount of this Note will be disbursed on the First Omnibus Amendment Effective Date to be used in accordance with Section 7.1(l).  The Second Additional Principal Amount of this Note will be disbursed on the Third Omnibus Amendment Effective Date to be used in accordance with Section 7.1(l). The Borrowers shall not have the right to redraw any amount prepaid or repaid hereunder.
(e)Section 3.6 of the MSD Secured Note is hereby amended in its entirety as  follows:
-2-

    3.6    Exit Fee.  As consideration for the agreements of the Lender under the Secured Note, the Borrowers agree to pay to the Lender an exit fee (the “Exit Fee”) in an amount equal to 3.80% of the aggregate principal amount of this Note on the Third Omnibus Amendment Effective Date, including accrued and capitalized interest earned through the Exit Fee Payment Date (as defined below), which Exit Fee shall be earned in full on the Third Omnibus Amendment Effective Date and due and payable on the earliest to occur (such earliest date, the “Exit Fee Payment Date”) of (a) the Maturity Date and (b) the date on which all the Obligations are repaid, prepaid or required to be repaid or prepaid in full in cash (whether by scheduled maturity, voluntary prepayment, required prepayment, acceleration, demand, or otherwise). For the avoidance of doubt, the Exit Fee shall replace in full, and without any duplication of, the Exit Fee as defined under this Agreement and in existence immediately prior to the Third Omnibus Amendment Effective Date.
(f)Section 7.1(l) of the MSD Secured Note is hereby amended in its entirety as follows:
(l)    (a) use the net proceeds of the Initial Principal Amount to repay in full, in cash, all non-contingent obligations under the Arena Notes and the MBI Secured Note on the Closing Date; (b) use the net proceeds of the Additional Principal Amount to repay in full, in cash, all non-contingent obligations under the Mako Note by no later than the first Business Day following the First Omnibus Amendment Effective Date provided for the avoidance of doubt that upon such repayment the Mako Note shall be terminated and any reinstatement or reissuance thereof shall not constitute Permitted Indebtedness hereunder; (c) use the net proceeds of the Second Additional Principal Amount solely in connection with the transactions listed on Schedule 7.1(l); and (d) use the net proceeds of this Note to pay fees, costs and expenses related to the Note Documents, including interest and principal payments, to pay the cash consideration for acquisitions, including fees, costs and expenses related to such acquisitions, and for general corporate purposes not in contravention of any Law or any Note Document. 
(g)Annex I to the MSD Secured Note is hereby amended by replacing the reference to “$39,296,568”.” appearing therein with “$43,296,568”.
(h)The MSD Secured Note is hereby amended by adding the new Schedule 7.1(l) attached hereto as Exhibit A.
2.Amendment to GA Secured Note.  Subject to the satisfaction of the conditions precedent to the Amendment Effective Date set forth in Section 4 below, the GA Secured Note is hereby amended by replacing each reference to “$39,296,568” appearing in Section 1.65 and Section 1.77 therein with “$43,296,568”.
-3-

3.Amendment to Intercreditor Agreement.  Subject to the satisfaction of the conditions precedent to the Amendment Effective Date set forth in Section 4 below, the Intercreditor Agreement is hereby amended by replacing the reference to “$39,296,568” appearing the definition of “MSD Agreement Cap” in Section 1.01 therein with “$43,296,568”. 
4.Conditions to Effectiveness.  This Amendment shall be effective as of the date when all of the following conditions have been satisfied (such date the “Amendment Effective Date”):
(a)    the Lenders shall have received a copy of this Amendment duly executed by each Borrower;
(b)    the Lenders shall have received a certificate from an authorized officer of the Parent Borrower in form and substance reasonably satisfactory to the Lenders certifying that the execution and performance of this Amendment by the Borrowers is not materially adverse to the Holders (as defined in the Preferred Equity Agreement) in accordance with Section 7.01(v) of the Second Amended and Restated Certificate of Designation of Series A Fixed Rate Preferred Stock of HC2 Broadcasting Holdings Inc. dated as of August 31, 2020;
(d)    Borrowers shall have paid all fees costs and expenses due and payable as of the date hereof under the MSD Secured Note and the GA Secured Note, including without limitation all attorney’s fees and expenses incurred by the Lenders; and
(e)    the representations and warranties set forth in Section 5 hereof shall be true and correct as of the date hereof.
5.Representations and Warranties of the Borrowers.  Each Borrower hereby represents and warrants to the Lenders as follows: 
(a)the execution and delivery of this Amendment, and the performance of the Amended MSD Secured Note, the Amended GA Secured Note, and the Amended Intercreditor Agreement (i) have been duly authorized by all proper and necessary action of the board of directors of such Borrower; and (ii) do not and will not conflict with (x) any material provision of Law or regulatory requirements to which such Borrower is subject, or (y) any charter, bylaw, stock provision, partnership agreement or other document pertaining to the organization, power or authority of such Borrower;
(b)there is no material outstanding decree, decision, judgment or order that has been issued by any court, Governmental Authority, agency or arbitration authority against such Borrower or its FCC Licenses; 
(c)(x)  no Borrower is in default under or with respect to any Contractual Obligation of such Borrower that could, either individually or in the aggregate reasonably be expected to result in a Material Adverse Change; or (y) no consent or approval of any public authority or any other third party is required as a condition to the validity of this Amendment;
-4-

(d)each of this Amendment, the Amended MSD Secured Note, the Amended GA Secured Note, the Amended Intercreditor Agreement, each Note Document (as defined in the Amended MSD Secured Note), and each Note Document (as defined in the Amended GA Secured Note) is the valid and legally binding obligation of such Borrower, enforceable against such Borrower in accordance with its respective terms;
(e)the representations and warranties contained in Section 7.3 of the Amended MSD Secured Note and in Section 7.3 of the Amended GA Secured Note are true, correct and complete in all material respects (except that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof) on and as of the date of this Amendment (except to the extent that such representations and warranties relate solely to an earlier date, in which case such representations and warranties shall be true and correct in all material respects (except that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof) as of such earlier date); and
(f)no Default or Event of Default has occurred and is continuing.
6.Further Assurances.  At any time upon the reasonable request of any Lender, each Borrower shall promptly execute and deliver to the Lenders any additional documents as such Lender shall reasonably request pursuant to the Amended MSD Secured Note and the other Note Documents (as defined in the Amended MSD Secured Note) or the Amended GA Secured Note and the other Note Documents (as defined in the Amended GA Secured Note), in each case in form and substance reasonably satisfactory to the Lenders.
7.Governing Law; Submission to Jurisdiction; Venue; Waiver of Jury Trial.  THIS AMENDMENT SHALL BE SUBJECT TO THE PROVISIONS REGARDING GOVERNING LAW, SUBMISSION TO JURISDICTION, VENUE, AND WAIVER OF JURY TRIAL SET FORTH IN SECTION 11 OF THE AMENDED SECURED NOTE, AND SUCH PROVISIONS ARE INCORPORATED HEREIN BY THIS REFERENCE, MUTATIS MUTANDIS.
8.Binding Effect.  This Amendment shall be binding upon the Borrowers and shall inure to the benefit of the Lenders, together with their respective successors and permitted assigns.
9.Effect on Note Documents.
(a)The terms and provisions set forth in this Amendment shall modify and supersede all inconsistent terms and provisions of the MSD Secured Note, the GA Secured Note, and the Intercreditor Agreement, and shall not be deemed to be a consent to or a modification or amendment of any other term or condition of the MSD Secured Note, the GA Secured Note, or the Intercreditor Agreement.  Except as expressly modified and superseded by this Amendment, the terms and provisions of the MSD Secured Note and each of the other Note Documents (as defined in the MSD Secured Note), the GA Secured Note and each of the other Note Documents (as defined in the GA Secured Note), and the Intercreditor Agreement are ratified and confirmed and shall continue in full force and effect.
-5-

(b)Each reference in the MSD Secured Note or any other Note Document (as defined in the MSD Secured Note) to this “Note”, “hereunder”, “herein”, “hereof”, “thereunder”, “therein”, “thereof”, or words of like import referring to the MSD Secured Note shall on and from the date hereof mean and refer to the Amended MSD Secured Note.
(c)Each reference in the GA Secured Note or any other Note Document (as defined in the GA Secured Note) to this “Note”, “hereunder”, “herein”, “hereof”, “thereunder”, “therein”, “thereof”, or words of like import referring to the GA Secured Note shall on and from the date hereof mean and refer to the Amended GA Secured Note.
(d)Each reference in the Intercreditor Agreement to this “Agreement”, “hereunder”, “herein”, “hereof”, “thereunder”, “therein”, “thereof”, or words of like import referring to the Intercreditor Agreement shall on and from the date hereof mean and refer to the Amended Intercreditor Agreement.
10.Miscellaneous
(a)This Amendment is a “Note Document” under both the Amended MSD Secured Note and the Amended GA Secured Note.  This Amendment may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, shall be deemed to be an original, and all of which, taken together, shall constitute but one and the same instrument.  Delivery of an executed counterpart of this Amendment by telefacsimile or other electronic image scan transmission (e.g., “PDF” or “tif” via email) shall be equally effective as delivery of a manually executed counterpart of this Amendment.
(b)If any term or provision of this Amendment is invalid, illegal or unenforceable in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other term or provision of this Amendment or invalidate or render unenforceable such term or provision in any other jurisdiction.  Upon such determination that any term or other provision is invalid, illegal or unenforceable, the Parties hereto shall negotiate in good faith to modify this Amendment so as to effect the original intent of the parties as closely as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the greatest extent possible.
(c)The headings of the various Sections and subsections herein are for reference only and shall not define, modify, expand or limit any of the terms or provisions hereof.
(d)This Amendment shall be construed without regard to any presumption or rule requiring construction or interpretation against the party drafting an instrument or causing any instrument to be drafted.
[remainder of this page intentionally left blank]

-6-

IN WITNESS WHEREOF, the Borrowers and the Lenders have caused this Amendment to be duly executed by its authorized officer as of the day and year first above written.
HC2 Broadcasting Holdings Inc., 
as the Parent Borrower

By:        /s/ Ivan P. Minkov                
    Name:    Ivan P. Minkov
    Title:    Chief Financial Officer

HC2 BROADCASTING INTERMEDIATE Holdings Inc., 
as the Intermediate Borrower

By:         /s/ Ivan P. Minkov               
    Name:    Ivan P. Minkov
    Title:    Chief Financial Officer

HC2 STATION GROUP, INC.,
as a Subsidiary Borrower

By:        /s/ Ivan P. Minkov                
    Name:    Ivan P. Minkov
    Title:    Chief Financial Officer

HC2 LPTV HOLDINGS, INC., 
as a Subsidiary Borrower

By:        /s/ Ivan P. Minkov                
    Name:    Ivan P. Minkov
    Title:    Chief Financial Officer

Signature Page to Third Omnibus Amendment

HC2 BROADCASTING INC., 
as a Subsidiary Borrower

By:          /s/ Ivan P. Minkov              
    Name:    Ivan P. Minkov
    Title:    Chief Financial Officer

HC2 NETWORK INC., 
as a Subsidiary Borrower

By:          /s/ Ivan P. Minkov              
    Name:    Ivan P. Minkov
    Title:    Chief Financial Officer

Signature Page to Third Omnibus Amendment

MSD PCOF PARTNERS XVIII, LLC

By:      /s/ Marcello Liguori        
    Name:    Marcello Liguori
    Title:    Vice President

Signature Page to Third Omnibus Amendment

GREAT AMERICAN LIFE INSURANCE                                 COMPANY

By:      /s/ Mark F. Muething        
    Name:    Mark F. Muething
    Title:    President

GREAT AMERICAN INSURANCE                                 COMPANY

By:      /s/ Stephen C. Beraha        
    Name:    Stephen C. Beraha
    Title:    Assistant Vice President
    

Signature Page to Third Omnibus Amendment

Exhibit A
Schedule 7.1(l)
Second Additional Principal Amount: Use of Proceeds
1.Settlement of the Rohde & Schwartz litigation: $1,730,000
2.Contingent consideration due for previous station purchases: $250,000 ($200,000 for KOHC/Sunshine State and $50,000 for WPVN/Polenet)
3.Partial payment of certain other stations vendor accounts payable: $2,020,000
a.American Tower Corporation: $1,758,895
b. Elettronika: $429,739
c. Hitachi Kokusai: $466,661
d.Other station equipment vendors: approximately $500,000Document

AMENDMENT NO. 1 TO AMENDED AND RESTATED LICENSE AGREEMENT
This Amendment No. 1 to the Amended and Restated License Agreement between Evofem, Inc., as Licensee (“LICENSEE”), and Rush University Medical Center (“RUSH”), as Licensor, (“Amendment No. 1”), is effective on the Effective Date, defined as the latter date of execution below and is made with reference to the following:
WHEREAS LICENSEE and RUSH are parties to a March 27, 2014 Amended and Restated License Agreement (“the License Agreement”) and now wish to amend certain provisions of the License Agreement as provided below; capitalized terms not otherwise defined herein shall have the meanings assigned to such terms in the License Agreement;
NOW, THEREFORE, in consideration of the mutual covenants and promises contained in the License Agreement and in this Amendment No. 1 and other good and valuable consideration described below, the receipt and sufficiency of which is hereby acknowledged by the parties, and intending to be legally bound, RUSH and LICENSEE agree:
1.The following amendments shall be made to the License Agreements:

a.The definition of “Know How” set forth in Section 1.6 of the License Agreement shall be restated in its entirety to read:

““Know how” shall mean, all know-how, non-patented inventions, improvements, discoveries, data, instructions, processes, formulas, sequences, information (including, without limitation, chemical, physical and analytical, safety, manufacturing and quality control data and information), procedures, devices, methods and trade secrets that, in each case, are owned or controlled by RUSH as of the Effective Date or that are conceived, discovered or invented by RUSH during the term of the License Agreement, and which are necessary or appropriate to develop and commercialize Technology.”

b.The definition of “Net Sales” set forth in Section 1.8 of the License Agreement shall be restated in its entirety to read:

““Net Sales” means, for any period of determination, the gross amount received for Products by LICENSEE or affiliates from Third Parties for such period of determination, less the aggregate of the following deductions to the extent actually incurred in connection with such sales:
(a)reasonable and customary cash, trade, and quantity discounts off the invoiced price, promotional allowances and fees to wholesalers and retailers based on the sale or dispensing of Products;

(b)excise, sales, value added, goods and services and other consumption taxes and import/export and custom duties or other taxes imposed on the importation, use or sale of the Product to Third Parties, to the extent included in the gross amount invoiced; 

(c)freight, insurance and other transportation charges, to the extent billed separately (it being understood that for routine shipments to drug wholesalers and chain drug warehouses, freight, insurance and other transportation charges are an operating expense that is not billed separately, and should not be included as a reduction in gross sales to calculate Net Sales, whereas certain accounts may incur freight charges that are billed separately, and that amount for freight would be included as a reduction in gross sales in the calculation of Net Sales);

(d)amounts repaid, credited or accrued, or allowances or adjustments made, by reason of customer returns, rejections, or recalls;

(e)retroactive corrections including price adjustments (including those on customer inventories following price changes) and corrections for billing errors or shipping errors;

(f)chargebacks, rebates, administrative fees, any other allowances actually granted or allowed to any entity including, but not limited to group purchasing organizations, managed health care organizations and to governments, including their agencies, or to trade customers, in each case that are not Affiliates of LICENSEE, and which are directly attributable to the sale of the Products; and

(g)rebates associated with any voucher, coupon, loyalty card or other co-pay assistance programs; 

all of the above solely to the extent not in violation of applicable law and are taken in accordance with Generally Accepted Accounting Principles in the United States (GAAP).  

For avoidance of doubt, no allowance or deduction shall be made for commissions or fees for collection, by whatever name known. If LICENSEE or its Affiliates receive anything of value in lieu of cash payments in consideration for the sale, transfer, performance or other disposition of the Product or Process to any Third Party, LICENSEE shall assess a Net Sales value on such transaction based on the fair market value of such payment. If LICENSEE or its Affiliates are the end user of a Product or Process, the Net Sales from each such use shall be that invoiced by LICENSEE to a Third Party end user of the same Product or Process. If no such Third Party end users exist, RUSH and LICENSEE shall negotiate in good faith to determine an equitable Net Sales price.”

c.The definition of “Term” set forth in Section 1.14 of the License Agreement shall be restated in its entirety to read:

“”Term” means the period beginning on the Effective Date and extending to the expiration of the last to expire Patent or patent claiming an Improvement.  This includes any patent term extensions.”

d.The preamble of Section 6.3.2 shall be restated to read:

“Minimum Annual Royalty.  Commencing on January 1 of year one (1) after a Product or Process has received Regulatory Approval as is introduced to market, to the extent that the amounts paid to RUSH as earned royalties or sublicensing fees do not total the amount set forth hereinafter, LICENSEE shall to RUSH a Minimum Annual Royalty as follows: “

All other sections of Section 6.3.2 remain the same.

e.Section 6.4 shall be restated in its entirety to read:

“Time of Payments. Amounts owing to RUSH shall be paid on a quarterly basis, with such amounts due and paid on or before the fifth (5th) Business Day (defined as any day except weekends and holidays observed by the U.S. Federal Reserve System) after LICENSEE files its 10-Q/10-K with the SEC for such quarter/year, as applicable, with the SEC. The balance of any amounts owing RUSH which remain unpaid more than thirty (30) days after they are due to RUSH shall accrue interest until paid at the rate of the lesser of one percent (1%) per month or the maximum allowed under applicable law. However, in no event shall this interest provision be construed as a grant of permission for any payment delays.”

f.Section 6.7 shall be restated as follows:
“Place of Payment.  All royalty payments and reports shall be sent to:
Rush University Medical Center
Attention: Bhaskar Chetnani, PhD
Innovation and Technology Transfer
Jelke Building, Sixth Floor
1653 W. Congress Parkway
Chicago, IL 60612”

g.Sections 10.6 and 10.7 shall be deleted in their entirety and shall have no force or effect. Further, such provisions were mooted by reason of LICENSEE’s continuous, diligent exploitation of the licensed Patent(s), Improvements and/or Know-how and therefore any and all rights thereunder have been and hereby are finally and forever waived. 

2.Payment. Within five (5) Business Days of the Effective Date, LICENSEE shall pay RUSH the sum of fifty-thousand dollars ($50,000.00).

3.General. Except as specifically amended or deleted hereby, all other terms of the License Agreement shall remain in full force and effect.  In case any provision of or obligation under this Amendment No. 1 shall be invalid, illegal or unenforceable the remaining provisions or obligations shall not in any way be affected or impaired thereby. This Amendment No. 1 may be executed and delivered via facsimile or pdf with the same force and effect as if an original were executed and may be signed in any number of counterparts, each of which shall be an original, with the same effect as if the signatures hereto were upon the same instrument. This 

Amendment No. 1 constitutes the entire agreement and understanding among the parties hereto with respect to the subject matter hereof and supersede any and all prior agreements and understandings, oral or written, relating to the subject matter hereof.

IN WITNESS WHEREOF, the parties intending to be legally bound have caused this Agreement to be executed by their duly authorized representatives as of the last date signed below.

															
	“LICENSEE” (Evofem, Inc.)
		“RUSH”    (Rush University Medical Center)

	By:
	/s/ Justin J. File
		By:	/s/ Andrew J Bean
	Name:    Jay File
		Name:     Andrew J Bean, PhD

	Title:     Chief Financial Officer
		Title:    Associate Provost for Research

	Dated: September 29, 2020		Dated:     September 29, 2020

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}]]